New tricks for old drugs: combination of rituximab and two nanoparticle-delivered chemotherapy drugs, albumin-bound paclitaxel and pegylated liposomal doxorubicin, in the treatment of relapsed/refractory diffuse large B cell lymphoma

Leuk Lymphoma. 2020 Oct;61(10):2502-2506. doi: 10.1080/10428194.2020.1775206. Epub 2020 Jun 6.

Authors

Liang Wang¹, Xiao-Qin Chen², Zhong-Jun Xia²

Affiliations

¹ Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
² Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

PMID: 32508171
DOI: 10.1080/10428194.2020.1775206

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Albumin-Bound Paclitaxel / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Cyclophosphamide / therapeutic use
Doxorubicin / analogs & derivatives
Doxorubicin / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Nanoparticles*
Pharmaceutical Preparations*
Polyethylene Glycols
Rituximab / therapeutic use
Treatment Outcome

Substances

Albumin-Bound Paclitaxel
Pharmaceutical Preparations
liposomal doxorubicin
Polyethylene Glycols
Rituximab
Doxorubicin
Cyclophosphamide